DVX-201 by Coeptis Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

Related Keywords

Wexford ,Pennsylvania ,United States , ,Globaldata Pharmaceutical Intelligence Center ,Coeptis Therapeutics ,Refractory Acute Myeloid ,Refractory Acute Myeloid Leukemia ,Phase Transition Success Rate Model ,Pharmaceutical Intelligence ,